In this subtitle the following words have the meanings indicated. “Biologic” means a drug that is produced or distributed in accordance with a biologics license application approved under 42 C.F.R. § 447.502. “Biosimilar” means a drug that is produced or distributed in accordance with a biologics license application approved under 42 U.S.C. § 262(k)(3). “Board” means the Prescription Drug Affordability Board. “Brand name drug” means a drug that is produced or distributed in accordance with an original new drug application approved under 21 U.S.C. § 355(c). “Brand name drug” does not include an authorized generic as defined by 42 C.F.R. § 447.502. “Current shortage” means a drug: Listed as current on the federal Food and Drug Administration’s Drug Shortage Database; or Otherwise determined by the Board to be in short supply in the State. “Generic drug” means: A retail drug that is marketed or distributed in accordance with an abbreviated new drug application, approved under 21 U.S.C. § 355(j); An authorized generic as defined by 42 C.F.R. § 447.502; or A drug that entered the market before 1962 that was not originally marketed under a new drug application. “Manufacturer” means an entity that: Engages in the manufacture of a prescription drug product; or Enters into a lease with another manufacturer to market and distribute a prescription drug product under the entity’s own name; and Sets or changes the wholesale acquisition cost of the prescription drug product it manufactures or markets. “Prescription drug product” means a brand name drug, a generic drug, a biologic, or a biosimilar. “Stakeholder Council” means the Prescription Drug Affordability Stakeholder Council.